Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
NCT ID: NCT00825721
Last Updated: 2009-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
81 participants
INTERVENTIONAL
2007-11-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FLACS vs Phaco in Shallow Anterior Chamber
NCT03587909
IOP Changes Associated With SICS and Phako
NCT02642211
Microinterventional Endocapsular Nuclear Fragmentation Assisted Cataract Surgery
NCT05736042
Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
NCT03106402
Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial
NCT01385878
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1.3% (low dose)
C-KAD Ophthalmic Solution
4 drops applied daily for 360 days
2% (medium dose)
C-KAD Ophthalmic Solution
4 drops applied daily for 360 days
2.6% (high dose)
C-KAD Ophthalmic Solution
4 drops applied daily for 360 days
Placebo
LiquiTears
4 drops applied daily for 360 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LiquiTears
4 drops applied daily for 360 days
C-KAD Ophthalmic Solution
4 drops applied daily for 360 days
C-KAD Ophthalmic Solution
4 drops applied daily for 360 days
C-KAD Ophthalmic Solution
4 drops applied daily for 360 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCDVA within the range of 20/40 and 20/80
Exclusion Criteria
* Presence or history of glaucoma
* Presence or history of diabetes
* Use of eyedrops
* Use of steroids
35 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chakshu Research, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chakshu Reserach, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sanduk Ruit, MD
Role: PRINCIPAL_INVESTIGATOR
Tilganga Eye Center
Reeta Gurung, MD
Role: PRINCIPAL_INVESTIGATOR
Tilganga Eye Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tilganga Eye Center
Kathmandu, Kathmandu, Nepal
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CK-0105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.